Author:
Leal Justin,Wellman Samuel S.,Jiranek William A.,Seyler Thorsten M.,Bolognesi Michael P.,Ryan Sean P.
Abstract
Background:
This retrospective study investigated the impact of continuing vs discontinuing home oral hypoglycemic medications for patients with diabetes undergoing total hip arthroplasty.
Materials and Methods:
Patients who were not exclusively receiving home oral hypoglycemic regimens were excluded. Additionally, patients whose diabetes was not managed inpatient postoperatively were excluded. Included patients were retrospectively evaluated for early postoperative glycemic control, renal function, and metabolic abnormalities. Patients were then compared based on whether their home oral hypoglycemic regimen was continued vs discontinued in favor of initiating insulin while inpatient and analyzed using multivariable regression analysis.
Results:
A total of 532 patients undergoing total hip arthroplasty met inclusion criteria, with 78.6% continuing their home oral hypoglycemic regimen. Those who continued showed significantly lower median maximum inpatient blood glucose (178.5 mg/dL vs 249.5 mg/dL;
P
<.001) and median average inpatient blood glucose (138.4 mg/dL vs 178.6 mg/dL;
P
<.001). Linear regression analysis, adjusting for various potential confounding factors, revealed a positive correlation between discontinuation of home hypoglycemic medications and higher maximum in-patient blood glucose (β=70.15 [95% CI, 59.27–81.03];
P
<.001). Patients in the continuation group had lower proportions of acute kidney injury (18.7% vs 41.2%;
P
<.001) and metabolic acidosis (4.3% vs 17.5%;
P
<.001), along with a shorter length of stay (1.0 d vs 2.0 d;
P
<.001).
Conclusion:
These findings suggest that continuing a home oral hypoglycemic regimen for patients with diabetes after total hip arthroplasty is associated with superior glycemic control without exacerbating renal abnormalities or increasing metabolic complications. [
Orthopedics
. 202x;4x(x):xx–xx.]